title: Association of vitamin D status and blood pressure response after renal denervation.
abstract: BACKGROUND
  Vitamin D deficiency is associated with hypertension; however, it is unclear whether vitamin D influences therapeutic blood pressure reduction. Renal sympathetic denervation (RDN) reduces blood pressure in resistant hypertension. We hypothesized that vitamin D might influence blood pressure response to RDN.
  
  
  METHODS
  Vitamin D was measured in 101 patients with resistant hypertension undergoing RDN. The associations between vitamin D status and systolic blood pressure (SBP) reduction 6 months after RDN were analyzed.
  
  
  RESULTS
  Mean office SBP at baseline was 171.5 ± 2 mmHg. After RDN, mean office SBP was reduced by 28.4 ± 2.3 mmHg (p = 0.007). 85 patients (84.2 %) had SBP reductions >10 mmHg (responders). Vitamin D concentrations were lower in non-responders as compared to responders (9.9 ± 4.5 vs. 13.7 ± 7.4 ng/ml, p = 0.008). Non-responders (n = 16, 15.8 %), more often had a vitamin D concentration below the median as compared to responders (81 vs. 46 %, p = 0.013). The percentage of patients with normal vitamin D concentrations increased with increasing tertiles of SBP reduction (p for trend = 0.020). In patients with vitamin D concentrations below the median, SBP reduction was lower as compared to patients with a vitamin D concentration above the median (23.5 ± 3.2 vs. 33.7 ± 3.2 mmHg, p = 0.026). Baseline vitamin D concentrations correlated with SBP reduction (r = 0.202, p = 0.043).
  
  
  CONCLUSIONS
  In patients with resistant hypertension, low vitamin D concentrations were associated with a decreased SBP response and a higher rate of non-response.
authors.affiliation: Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Straße, 66421, Homburg/Saar, Germany, Janine.poess@uks.eu.
authors.forename: Janine
authors.initials: J
authors.lastname: Pöss
authors.forename: Felix
authors.initials: F
authors.lastname: Mahfoud
authors.forename: Christian
authors.initials: C
authors.lastname: Ukena
authors.forename: Murray David
authors.initials: MD
authors.lastname: Esler
authors.forename: Markus
authors.initials: M
authors.lastname: Schlaich
authors.forename: Dagmara
authors.initials: D
authors.lastname: Hering
authors.forename: Bodo
authors.initials: B
authors.lastname: Cremers
authors.forename: Ulrich
authors.initials: U
authors.lastname: Laufs
authors.forename: Michael
authors.initials: M
authors.lastname: Böhm
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D017763:Autonomic Denervation; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D003430:Cross-Sectional Studies; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D007668:Kidney / Q000294:innervation*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications* / Q000175:diagnosis
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D014807:Vitamin D; C104450:25-hydroxyvitamin D